A multicenter, open, long term safety study of 52 weeks treatment with vildagliptin in patients with type 2 diabetes
Phase of Trial: Phase III
Latest Information Update: 13 May 2016
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novartis
- 06 Jan 2009 Status changed from active, no longer recruiting to completed.
- 23 Nov 2006 Status change from Recruiting to In Progress
- 12 Nov 2006 New trial record.